
TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus ...
Background Mutations of the ESR1 gene are thought to drive resistance to endocrine therapy (ET) in patients with estrogen receptor–positive/HER2-negative (ER+/HER2–) metastatic breast cancer, especially after a CDK4/6i inhibitor (CDK4/6i). …